Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$36.21 USD
+0.05 (0.14%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $36.20 -0.01 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AGIO 36.21 +0.05(0.14%)
Will AGIO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Other News for AGIO
12 Health Care Stocks Moving In Monday's Intraday Session
Agios Pharmaceuticals (AGIO) Stock Declines Nearly 18%
Agios Pharmaceuticals falls -17.8%
Agios Pharmaceuticals (AGIO) Stock Plummets 23% After Safety Concerns
Agios Pharmaceuticals (AGIO) Shares Plummet Over 20%